Amgen joins Kernal Bio’s $25M financing as the startup brings mRNA 2.0 to cancer
Kernal Biologics has technology that enables the delivery of messenger RNA therapies to a wider range of destinations in the body. The Series A financing comes as the startup works to advance its lead immuno-oncology program toward its first clinical test.